Related references
Note: Only part of the references are listed.Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations
B. Weigelt et al.
ANNALS OF ONCOLOGY (2012)
Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
Catherine M. Kelly et al.
ONCOLOGIST (2012)
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
Zsuzsanna Varga et al.
PLOS ONE (2012)
Decentral gene expression analysis for ER+/Her2-breast cancer: results of a proficiency testing program for the EndoPredict assay
Carsten Denkert et al.
VIRCHOWS ARCHIV (2012)
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
Foluso O. Ademuyiwa et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
Gong Tang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
S. Sahebjam et al.
BRITISH JOURNAL OF CANCER (2011)
Personalized Medicine: The Road Ahead
Rutika Mehta et al.
CLINICAL BREAST CANCER (2011)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits et al.
CLINICAL CANCER RESEARCH (2011)
Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue-A New Option for Predictive Biomarker Assessment in Breast Cancer
Berit Maria Mueller et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2011)
Knowledge About Genomic Recurrence Risk Testing Among Breast Cancer Survivors
Isaac M. Lipkus et al.
JOURNAL OF CANCER EDUCATION (2011)
High False- Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
David J. Dabbs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic or Predictive? It's Time to Get Back to Definitions!
Antoine Italiano
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score
Arif H. Kamal et al.
ONCOLOGIST (2011)
Knowledge of genomic testing among early-stage breast cancer patients
Alice R. Richman et al.
PSYCHO-ONCOLOGY (2011)
Proliferation (Ki-67 and Phosphohistone H3) and Oncotype DX Recurrence Score in Estrogen Receptor-positive Breast Cancer
Daron J. Williams et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
Utility of Oncotype DX Risk Estimates in Clinically Intermediate Risk Hormone Receptor-Positive, HER2-Normal, Grade II, Lymph Node-Negative Breast Cancers
Catherine M. Kelly et al.
CANCER (2010)
Women's Experiences With Genomic Testing for Breast Cancer Recurrence Risk
Janice P. Tzeng et al.
CANCER (2010)
The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features
Joseph Geradts et al.
CANCER INVESTIGATION (2010)
Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
Kyoko Yorozuya et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Concordance Between Semiquantitative Immunohistochemical Assay and Oncotype DX RT-PCR Assay for Estrogen and Progesterone Receptors
Siobhan M. O'Connor et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome
Jeffrey S. Ross
ADVANCES IN ANATOMIC PATHOLOGY (2009)
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
Kathy S. Albain et al.
BREAST (2009)
Recent advances in systemic therapy New diagnostics and biological predictors of outcome in early breast cancer
Catherine Oakman et al.
BREAST CANCER RESEARCH (2009)
Systematic review: Gene expression profiling assays in early-stage breast cancer
Luigi Marchionni et al.
ANNALS OF INTERNAL MEDICINE (2008)
Histopathologic variables predict Oncotype DX™ Recurrence Score
Melina B. Flanagan et al.
MODERN PATHOLOGY (2008)
Commercialized multigene predictors of clinical outcome for breast cancer
Jeffrey S. Ross et al.
ONCOLOGIST (2008)
Molecular profiling in breast cancer
Shannon R. Morris et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Laurel A. Habel et al.
BREAST CANCER RESEARCH (2006)
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer
Z Varga et al.
VIRCHOWS ARCHIV (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)